From: High dose simultaneous integrated boost for node positive cervical cancer
Overall (n = 69) | EBRT with SIB (n = 23) | EBRT without SIB (n = 46) | P value | |
---|---|---|---|---|
Age | ||||
Median (years) | 53.0 | 40.0 | 61.5 | < 0.05 |
Range (years) | 25–89 | 25–64 | 29–89 | |
Follow up | ||||
Median (months) | 30.9 | 31.5 | 30.2 | 0.52 |
Range (months) | 1.4–79.3 | 2.2–52.2 | 1.4–79.3 | |
Histology | ||||
Squamous carcinoma | 53 (77%) | 20 (87%) | 33 (72%) | 0.11 |
Adenocarcinoma | 12 (17%) | 1 (4%) | 11 (24%) | |
AdenoSquamous | 4 (6%) | 2 (9%) | 2 (4%) | |
FIGO stage | ||||
IB | 12 (17%) | 2 (9%) | 10 (22%) | < 0.05 |
IIA | 10 (15%) | 2 (9%) | 8 (18%) | |
IIB | 36 (52%) | 11 (48%) | 25 (54%) | |
IIIA | 1 (1%) | 1 (4%) | 0 | |
IIIB | 6 (9%) | 5 (21%) | 1 (2%) | |
IVA | 4 (6%) | 2 (9%) | 2 (4%) |